Galectin Therapeutics, Inc. (GALT) Stock Is An 52-Week High Flier

June 14, 2018 - By Marie Mckinney

Galectin Therapeutics, Inc. (NASDAQ:GALT) Logo

Investors sentiment increased to 1.86 in Q1 2018. Its up 1.33, from 0.53 in 2017Q4. It increased, as 7 investors sold Galectin Therapeutics, Inc. shares while 7 reduced holdings. 17 funds opened positions while 9 raised stakes. 4.02 million shares or 30.74% more from 3.08 million shares in 2017Q4 were reported.
Cutter And Brokerage Inc accumulated 53,600 shares or 0.1% of the stock. Riggs Asset Managment has 1,000 shares. Dynamic Advisor Solutions Limited Liability Company reported 10,000 shares or 0.01% of all its holdings. The United Kingdom-based Rathbone Brothers Public Llc has invested 0% in Galectin Therapeutics, Inc. (NASDAQ:GALT). Sabby Management Ltd Limited Liability Company holds 0.08% in Galectin Therapeutics, Inc. (NASDAQ:GALT) or 143,400 shares. Element Ltd Liability Com has invested 0% in Galectin Therapeutics, Inc. (NASDAQ:GALT). Stratos Wealth Prtn Limited holds 0.01% or 28,154 shares in its portfolio. Citadel Advsr Ltd Liability Company reported 67,546 shares. Jefferies Group Limited Liability accumulated 20,000 shares or 0% of the stock. Gp One Trading L P has 5,152 shares. 8,260 are owned by Natl Bank Of America De. Royal Bancorp Of Canada owns 600 shares or 0% of their US portfolio. Vanguard Group Inc Inc holds 1.17 million shares. Bankshares Of Mellon Corp accumulated 25,809 shares. Da Davidson holds 731,300 shares.

Since January 25, 2018, it had 2 insider purchases, and 16 insider sales for $8.38 million activity. Shares for $233,255 were sold by CALLICUTT JACK W on Thursday, May 31. $8,191 worth of stock was bought by FREEMAN KEVIN D on Thursday, February 1. CZIRR JAMES C had sold 110,000 shares worth $646,800. ZUCCONI THEODORE DANIEL sold $14,320 worth of Galectin Therapeutics, Inc. (NASDAQ:GALT) on Monday, April 16. On Thursday, January 25 the insider 10X Fund – L.P. sold $1.33 million. 70,000 Galectin Therapeutics, Inc. (NASDAQ:GALT) shares with value of $409,997 were sold by TRABER PETER G.

The stock of Galectin Therapeutics, Inc. (NASDAQ:GALT) hit a new 52-week high and has $8.37 target or 6.00 % above today’s $7.90 share price. The 7 months bullish chart indicates low risk for the $298.15M company. The 1-year high was reported on Jun, 14 by If the $8.37 price target is reached, the company will be worth $17.89M more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock.

The stock increased 1.02% or $0.08 during the last trading session, reaching $7.9. About 1.67 million shares traded or 169.94% up from the average. Galectin Therapeutics, Inc. (NASDAQ:GALT) has risen 77.97% since June 14, 2017 and is uptrending. It has outperformed by 65.40% the S&P500.

Analysts await Galectin Therapeutics, Inc. (NASDAQ:GALT) to report earnings on August, 13. They expect $-0.14 earnings per share, 0.00 % or $0.00 from last year’s $-0.14 per share. After $-0.12 actual earnings per share reported by Galectin Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 16.67 % negative EPS growth.

More notable recent Galectin Therapeutics, Inc. (NASDAQ:GALT) news were published by: which released: “38 Biggest Movers From Yesterday” on June 14, 2018, also with their article: “Galectin Therapeutics Inc. Announces New CEO” published on June 12, 2018, published: “Mid-Day Market Update: Pivotal Software Gains Following Q1 Results; Flex Pharma Shares Slide” on June 13, 2018. More interesting news about Galectin Therapeutics, Inc. (NASDAQ:GALT) were released by: and their article: “36 Biggest Movers From Friday” published on June 11, 2018 as well as‘s news article titled: “Galectin Therapeutics (GALT) Names Harold H. Shlevin as New CEO; Peter G. Traber Resigns” with publication date: June 12, 2018.

Galectin Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic disease and cancer. The company has market cap of $298.15 million. The companyÂ’s lead product candidate includes galectin-3 inhibitor , a galactoarabino-rhamnogalacturonan polysaccharide polymer for the treatment of liver fibrosis and liver cirrhosis in non-alcoholic steatohepatitis patients, as well as for the treatment of cancer. It currently has negative earnings. It also engages in developing GM-CT-01, which is in pre-clinical development state for the treatment of cardiac and vascular fibrosis, as well as focuses on developing GR-MD-02 for the treatment of psoriasis.

Galectin Therapeutics, Inc. (NASDAQ:GALT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: